atrasentan has been researched along with Chronic Kidney Diseases in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (57.69) | 24.3611 |
| 2020's | 11 (42.31) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, G; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Rossing, P; Xie, D | 1 |
| Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, DE; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Tobe, S; Waijer, SW | 1 |
| Bakris, GL; Correa-Rotter, R; de Zeeuw, D; Heerspink, HJL; Hou, FF; Januzzi, JL; Kitzman, DW; Kohan, DE; Kolansky, DM; Koomen, J; Makino, H; McMurray, JJV; Parving, HH; Perkovic, V; Smeijer, JD; Tobe, S | 1 |
| Barratt, J; Heerspink, HJL; Kohan, DE; Liew, A; Tang, SCW | 1 |
| Chan, KW; de Zeeuw, D; Gansevoort, RT; Heerspink, HJL; Jongs, N; Kohan, DE; Liew, A; Schechter, M; Smeijer, JD; Tang, SCW; Vart, P; Wanner, C | 1 |
| Correa-Rotter, R; de Zeeuw, D; Gansevoort, RT; Ju, W; Kohan, DE; Lambers Heerspink, HJ; Liew, A; Rossing, P; Smeijer, JD; Tang, SCW | 1 |
| Liu, D; Liu, Z | 1 |
| Libetta, C; Sepe, V | 1 |
| de Zeeuw, D; Heerspink, HJL; Parving, HH | 1 |
| Andreucci, M; De Nicola, L; Garofalo, C; Minutolo, R; Provenzano, M; Serra, R | 1 |
| Dhaun, N; Heerspink, HJL; Kohan, DE; Smeijer, JD; Webb, DJ | 1 |
| Egido, J; Gomez-Guerrero, C; Gonzalez Parra, E; Mas, S; Rojas-Rivera, J; Ruiz-Ortega, M; Sanz, AB | 1 |
| Andress, DL; Bakris, G; Brennan, JJ; Correa-Rotter, R; de Zeeuw, D; Dey, J; Heerspink, HJL; Hou, FF; Kitzman, DW; Kohan, D; Makino, H; McMurray, J; Parving, HH; Perkovic, V; Tobe, S; Wigderson, M | 1 |
| Heerspink, HJL; Muskiet, MHA; Wheeler, DC | 1 |
| Tuttle, KR | 1 |
| Pollock, DM; Pollock, JS | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| Angelini, ML; Baraldi, O; Cianciolo, G; Iorio, M; Stefoni, S | 1 |
| Liu, KD | 1 |
| Kang, JJ; Kang, PM; Ke, Q; Kim, UK; Samad, MA | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Hoekman, J; Hou, FF; Kitzman, DW; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Remuzzi, G; Schievink, B; Smink, PA; Tobe, S; Toto, R | 1 |
| Batu Demir, D; Cooper, ME | 1 |
| Breyer, MD; Susztak, K | 1 |
| Agharazii, M; Gauthier-Bastien, A; Larivière, R; Mac-Way, F; Richard, DE; St-Hilaire, J; Ung, RV | 1 |
| Andress, DL; Brennan, J; Coll, B; Kohan, DE; Molitch, M; Pritchett, Y | 1 |
| Certíková Chábová, V; Červenka, L; Husková, Z; Kramer, HJ; Kujal, P; Skaroupková, P; Tesař, V; Vaněčková, I; Vaňourková, Z; Vernerová, Z | 1 |
8 review(s) available for atrasentan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Proteinuria; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Renal Insufficiency, Chronic | 2021 |
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2021 |
Atrasentan for the treatment of diabetic nephropathy.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Proteinuria; Pyrrolidines; Renal Insufficiency, Chronic | 2017 |
New pharmacological strategies for protecting kidney function in type 2 diabetes.
Topics: Antihypertensive Agents; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Incretins; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Emerging drugs for chronic kidney disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Glycosaminoglycans; Humans; Pyridines; Pyridoxamine; Pyrimidines; Pyrrolidines; Renal Insufficiency, Chronic | 2014 |
Therapeutic strategies for clinical trials targeting renal recovery.
Topics: Acute Kidney Injury; Animals; Atrasentan; Biomarkers; Caloric Restriction; Clinical Trials as Topic; Disease Models, Animal; Fibrosis; Follow-Up Studies; Humans; Inflammation; Kidney; Kidney Function Tests; Mesenchymal Stem Cell Transplantation; Meta-Analysis as Topic; Pyrrolidines; Recovery of Function; Regeneration; Renal Insufficiency, Chronic; Renal Replacement Therapy; Respiratory Distress Syndrome; Risk Factors; Treatment Outcome | 2014 |
New strategies to tackle diabetic kidney disease.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Endothelin Receptor Antagonists; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Mineralocorticoid Receptor Antagonists; Naphthyridines; Pyrrolidines; Renal Artery; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Sympathectomy | 2016 |
Developing Treatments for Chronic Kidney Disease in the 21st Century.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atrasentan; Benzhydryl Compounds; Canagliflozin; Diabetic Nephropathies; Drug Discovery; Endothelin Receptor Antagonists; Glucosides; Glycosaminoglycans; Humans; Hypoglycemic Agents; Mineralocorticoid Receptor Antagonists; Oleanolic Acid; Oxidative Stress; Pyridoxamine; Pyrrolidines; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
7 trial(s) available for atrasentan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
Topics: Aged; Albuminuria; Atrasentan; Causality; Creatinine; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Reduction Behavior; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome | 2021 |
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
Topics: Albuminuria; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Renal Insufficiency; Renal Insufficiency, Chronic | 2021 |
Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Natriuretic Peptide, Brain; Renal Insufficiency, Chronic; Weight Gain | 2022 |
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin Receptor Antagonists; Humans; Pain; Renal Insufficiency, Chronic | 2023 |
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Kidney; Kidney Failure, Chronic; Male; Precision Medicine; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Severity of Illness Index | 2018 |
Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Atrasentan; Biomarkers; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2016 |
Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
Topics: Aged; Albuminuria; Atrasentan; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Edema; Endothelin A Receptor Antagonists; Female; Glomerular Filtration Rate; Hispanic or Latino; Humans; Male; Middle Aged; Pyrrolidines; Renal Insufficiency, Chronic; Renin-Angiotensin System | 2012 |
11 other study(ies) available for atrasentan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of atrasentan on markers of liver function in patients with type 2 diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Liver; Renal Insufficiency, Chronic | 2023 |
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Humans; Insulin Resistance; Kidney; Renal Insufficiency, Chronic | 2023 |
Atrasentan in patients with diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2020 |
Atrasentan in patients with diabetes and chronic kidney disease.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2020 |
Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply.
Topics: Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Humans; Renal Insufficiency, Chronic | 2020 |
A turning point for chronic kidney disease in diabetes.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Kidney; Renal Insufficiency, Chronic | 2019 |
SONAR propels endothelin A receptor antagonists to success.
Topics: Atrasentan; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Renal Insufficiency, Chronic | 2019 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.
Topics: Animals; Atrasentan; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Disease Models, Animal; Echocardiography; Endothelin A Receptor Antagonists; Gene Expression; Heart Diseases; Hemodynamics; Hypertension; Hypertrophy; Kidney Function Tests; Male; Myocytes, Cardiac; Phenylephrine; Pyrrolidines; Rats; Receptor, Endothelin A; Renal Insufficiency, Chronic | 2015 |
Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease.
Topics: Animals; Aorta, Thoracic; Atrasentan; Biomarkers; Blood Pressure; Calcium; Calgranulin A; Calgranulin B; Endothelin A Receptor Antagonists; Endothelin-1; Inflammation; Interleukin-1beta; Interleukin-6; Macrophages; Male; Phosphorus, Dietary; Pulse Wave Analysis; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Renal Insufficiency, Chronic; Tumor Necrosis Factor-alpha; Vascular Calcification; Vascular Stiffness; Vitamin D | 2017 |
Effects of combined endothelin A receptor and renin-angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Hypertension, Renal; Indoles; Kidney; Losartan; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Renal Insufficiency, Chronic; Renin-Angiotensin System; Survival Analysis; Treatment Outcome | 2012 |